Ich stimme zu, dass diese Seite Cookies verwende. Weitere Informationen finden Sie unter unseren Datenschutzerklärungen .
X
Johansen, O.E.
2872  Ergebnisse:
Personensuche X
?
1

The validity of heart failure diagnoses at hospital-dischar..:

Ofstad, A.P ; Johansen, O.E ; Brunborg, C...
European Heart Journal.  42 (2021)  Supplement_1 - p. , 2021
Link: https://doi.org/10.1093/..
 
?
2

Effects of linagliptin vs glimepiride stratified by prior i..:

McGuire, D.K ; Rosenstock, J ; Johansen, O.E...
European Heart Journal.  41 (2020)  Supplement_2 - p. , 2020
Link: https://doi.org/10.1093/..
 
?
3

Analysis of first plus recurrent cardiovascular (CV) and ho..:

Marx, N ; McGuire, D.K ; Johansen, O.E...
European Heart Journal.  41 (2020)  Supplement_2 - p. , 2020
Link: https://doi.org/10.1093/..
 
?
4

Impact of polyvascular disease and renal dysfunction on car..:

Verma, S ; Mazer, C.D ; Inzucchi, S.E...
European Heart Journal.  41 (2020)  Supplement_2 - p. , 2020
Link: https://doi.org/10.1093/..
 
?
5

P6270Empagliflozin reduces the total burden of first and re..:

McGuire, D ; Zinman, B ; Inzucchi, S E...
European Heart Journal.  40 (2019)  Supplement_1 - p. , 2019
Link: https://doi.org/10.1093/..
 
?
6

P1879Empagliflozin reduces mortality and hospitalisation fo..:

Fitchett, D ; Inzucchi, S E ; Cannon, C P...
European Heart Journal.  39 (2018)  suppl_1 - p. , 2018
Link: https://doi.org/10.1093/..
 
?
7

P3628Asymptomatic coronary artery disease in type 2 diabete..:

Ofstad, A P ; Arora, S ; Ulimoen, G R...
European Heart Journal.  39 (2018)  suppl_1 - p. , 2018
Link: https://doi.org/10.1093/..
 
?
8

P5272Concomitant heart failure (HF) and type 2 diabetes (T2..:

Ofstad, A.P. ; Atar, D. ; Gullestad, L...
European Heart Journal.  38 (2017)  suppl_1 - p. , 2017
Link: https://doi.org/10.1093/..
 
?
9

5935Effects of empagliflozin on cardiac and vascular hemody..:

Chilton, R.J. ; Gullestad, L. ; Fitchett, D....
European Heart Journal.  38 (2017)  suppl_1 - p. , 2017
Link: https://doi.org/10.1093/..
 
?
10

Effects of empagliflozin on blood pressure and markers of a..:

Chilton, R. ; Tikkanen, I. ; Cannon, C. P....
Diabetes, Obesity and Metabolism.  17 (2015)  12 - p. 1180-1193 , 2015
Link: https://doi.org/10.1111/..
 
?
11

P331 Efficacité et tolérance cardiovasculaire de la linagli..:

Zinman, B. ; Ahrén, B. ; Neubacher, D....
Diabetes & Metabolism.  41 (2015)  - p. A117 , 2015
Link: https://doi.org/10.1016/..
 
?
12

Empagliflozin as adjunct to insulin in patients with type 1..:

Pieber, T. R. ; Famulla, S. ; Eilbracht, J....
Diabetes, Obesity and Metabolism.  17 (2015)  10 - p. 928-935 , 2015
Link: https://doi.org/10.1111/..
 
?
13

OP5: Low Cardiovascular (CV) Risk Hazard Ratio Observed wit..:

Johansen, O.E. ; Neubacher, D. ; von Eynatten, M...
Diabetes & Metabolism.  38 (2012)  - p. S99-S100 , 2012
Link: https://doi.org/10.1016/..
 
?
14

P307 Risque cardiovasculaire avec Linagliptin chez des pati..:

Johansen, O.E. ; Neubacher, N. ; von Eynatten, M....
Diabetes & Metabolism.  38 (2012)  - p. A103 , 2012
Link: https://doi.org/10.1016/..
 
?
15

344 ELEVATED LEVELS OF FETUIN A IN NONALCOHOLIC FATTY LIVER..:

Haukeland, J.W. ; Konopski, Z. ; Aasheim, E....
Journal of Hepatology.  52 (2010)  - p. S143-S144 , 2010
Link: https://doi.org/10.1016/..
 
1-15